Drug Profile
Research programme: small molecule therapeutics - IFM Therapeutics
Alternative Names: NLRP antagonists - IFM therapeuticsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator IFM therapeutics
- Class Anti-inflammatories; Antidementias; Antigouts; Hepatoprotectants; Small molecules
- Mechanism of Action Immunomodulators; Inflammasome inhibitors; Inflammasome stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Gout; Inflammatory bowel diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Gout in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA